Utility of biochemical bone maker for evaluation of treatment in osteoporosis

Abstract

Biochemical bone markers (BMK) are known as bone turnover markers; they help us detect the bone turnover rate. Their principal utility is in evaluating the response to treatment. BMK play a limited role in the follow-up of patients with osteoporosis. Alterations of bone remodeling biomarkers reflect bone growth and bone turnover. In recent years, developed BMK are classified by bone remodeling process, including bone formation and bone resorption. Biomarkers of bone formation include bone-specific alkaline phosphatase, osteocalcin, procollagen type I C-, and N-terminal peptides (PICP and PINP). Biomarkers of bone resorption markers constitute deoxypyridinoline, C-terminal, and N-terminal crosslinking telopeptides of type I collagen (CTx and NTx). These laboratory measurements provide considerable improvements for the therapeutic evaluation of osteoporosis. Biochemical bone markers and evaluations of bone mass can assist in the optimization of the osteoporosis treatment.